Amgen Inc. buy melinda
Start price
31.08.17
/
50%
€176.34
Target price
12.09.17
€190.00
Performance (%)
7.96%
End price
12.09.17
€190.38
Summary
This prediction ended on 12.09.17 with a price of €190.38. The BUY prediction by melinda finished with a performance of 7.96%. melinda has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | 1.028% | 1.028% | 29.246% | 56.854% |
| iShares Core DAX® | 2.591% | 2.691% | 6.411% | 53.612% |
| iShares Nasdaq 100 | -0.915% | -7.368% | 20.651% | 72.782% |
| iShares Nikkei 225® | 0.145% | -10.196% | 46.169% | 62.432% |
| iShares S&P 500 | -0.367% | -0.833% | 18.019% | 60.744% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
$
Wenn in Phase III getestet Kopf an Kopf, das Bestreben, reduziert KYPROLIS und Dexamethason das Sterberisiko um 21% und erhöhte die Überlebenszeit von 7,6 Monaten im Vergleich zu Velcade und Dexamethason in Patienten mit rezidivierendem oder refraktärem multiplem Myelom